Thermo Fisher Scientific Cambridge Facility Wins the Queens Award for Enterprise in 2009
News Apr 29, 2009
Thermo Fisher Scientific Inc. has announced that its Cambridge facility has been awarded a Queens Award for Enterprise 2009 in the Outstanding Innovation category for the iCAP 6000 Series ICP-OES instrument. This award recognizes the iCAP 6000 as one of the year’s most outstanding technical innovations.
The Thermo Scientific iCAP 6000 Series ICP-OES (Inductively Coupled Plasma, Optical Emission Spectrometry) instruments are used in laboratories to detect and measure low levels of toxic or pollutant elements in a wide range of samples.
The Queens Award for Enterprise recognizes the novel design of the iCAP 6000 which delivers outstanding performance, ease of use and low cost of ownership, all in a compact instrument. Specifically developed for environmental, metallurgical, petrochemical and food safety applications, this compact instrument provides users in laboratories with increased analysis speed, stability and trace (parts per billion) level detection capabilities.
The Thermo Fisher Scientific team in Cambridge started work on the design of the iCAP 6000 in 2002 and has been manufacturing the product and distributing it world wide since 2006. Since its launch, the iCAP 6000 has captured a significant share of global markets in a number of important applications segments.
“The whole Cambridge team is delighted to be associated with a product which has been selected for this award” comments Paul Gillyon, product group director, Trace Elemental Analysis, Thermo Fisher Scientific.
“We work very hard to solve the technical challenges in developing complex instruments like the iCAP 6000 and to achieve commercial success with scientists in laboratories around the world. The Queens Award recognizes all the expertise, hard work and commitment that has been contributed by all the members of the Cambridge team.”
The Queen’s representative in Cambridge will make a formal presentation of the award at the Thermo Fisher Scientific facility, later in 2009.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE